# Why protein measurements and glucose measurements diverged in a diabetes model

- Article ID: research-205
- Product: IGF-DES 1,3 (igf-des-1-3-615)
- Canonical page: https://heritagebiolabs.com/research-library/articles/205-why-protein-measurements-and-glucose-measurements-diverged-in-a-diabetes-model
- Product collection: https://heritagebiolabs.com/research-library/products/igf-des-1-3
- Product page: https://heritagebiolabs.com/product/igf-des-1-3-615
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 1989, 1991

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptide bonds join amino acids into short chains called peptides. Growth factors built from amino acids can affect several aspects of metabolism. IGF-DES 1,3 refers here to des(1–3)IGF-1, the form missing the first three residues of mature insulin-like growth factor 1. An animal experiment asked how the shortened variant affected protein metabolism in rats with experimentally induced diabetes. [1, 2]

No recent primary study directly repeating this comparison was identified. In older work, the investigators compared full-length IGF-1 and the truncated variant with controls and with other hormone exposures in rats. They followed body weight, estimated nitrogen retention and measured protein synthesis in muscle. The shortened variant increased several of these measures compared with the injured metabolic state in control animals. The investigators found that increased synthesis contributed to the change in the body's overall nitrogen balance. [1]

They also looked at glucose in the urine. The IGF-related peptides did not reduce this sign of abnormal carbohydrate metabolism in the way insulin did in the experiment. The outcomes illustrate why protein synthesis, protein breakdown and glucose regulation should be assessed separately. A compound that changes one of these measures can have a different pattern on the others. [1]

The study describes a short period in a particular rat model. Protein synthesis measured under those conditions does not establish muscle strength or physical function, and the glucose result provides no evidence for treating human diabetes with the variant. The older findings are useful for understanding why a metabolic claim needs to identify the endpoint it is based on. [1]

## Sources

1. Tomas FM et al. Increased weight gain, nitrogen retention and muscle protein synthesis following treatment of diabetic rats with insulin-like growth factor (IGF)-I and des(1-3)IGF-I. Biochemical Journal (publication 1991-06-01). <https://pubmed.ncbi.nlm.nih.gov/1710892/>
2. Bagley CJ et al. A key functional role for the insulin-like growth factor 1 N-terminal pentapeptide. Biochemical Journal (publication 1989-05-01). <https://pubmed.ncbi.nlm.nih.gov/2730580/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 041 - IGF-DES 1 3.docx; article 205; content SHA-256 5f840555fdc24971aa0baceb6ea11320fa7259575c587301e55415d33225ea4c.
